The recent surge in the number of confirmed cases of COVID-19 in India has furthered the discussions on the propriety of exclusive patent rights in cases of national or global emergencies impacting public health and safety.1 The emergence of the virus in late 2019 and 2020 has led multilateral efforts involving, many pharmaceutical companies, research institutes and governmental agencies to venture into research and development of
vaccines to stem the onslaught of the virus. Many vaccines which have successfully rolled off testing and production, are already being administered to citizens worldwide;2 also, various vaccine diplomacy issues have come to the fore.
-and-Limited-partnerships-(LPs).jpg)
